Literature DB >> 22315235

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

Malcolm A Smith1, Min H Kang, C Patrick Reynolds, Raushan T Kurmasheva, Denise Alexander, Catherine A Billups, Jeffrey A Toretsky, Peter J Houghton.   

Abstract

Arsenic trioxide was tested against the PPTP in vitro panel (1.0 nM to 10 µM) and against the PPTP Ewing sarcoma in vivo panel administered intraperitoneally at a dose of 2.5 mg/kg daily × 5 per week for a planned treatment duration of 3 weeks. Arsenic trioxide showed a median relative IC(50) value of 0.9 µM, with Ewing sarcoma cell lines having IC(50) values similar to those of the remaining PPTP cell lines. Arsenic trioxide did not induce significant differences in EFS distribution compared to control in any of the Ewing sarcoma xenografts studied, and no objective responses were observed.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22315235      PMCID： PMC3612422          DOI： 10.1002/pbc.23391

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  20 in total

1.  National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing.

Authors:  Min H Kang; Malcolm A Smith; Christopher L Morton; Nino Keshelava; Peter J Houghton; C Patrick Reynolds
Journal:  Pediatr Blood Cancer       Date:  2010-10-04       Impact factor: 3.167

2.  Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway.

Authors:  Elspeth M Beauchamp; Lymor Ringer; Gülay Bulut; Kamal P Sajwan; Michael D Hall; Yi-Chien Lee; Daniel Peaceman; Metin Ozdemirli; Olga Rodriguez; Tobey J Macdonald; Chris Albanese; Jeffrey A Toretsky; Aykut Uren
Journal:  J Clin Invest       Date:  2010-12-22       Impact factor: 14.808

3.  Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector.

Authors:  Jynho Kim; John J Lee; James Kim; Dale Gardner; Philip A Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-12       Impact factor: 11.205

4.  Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.

Authors:  C Niu; H Yan; T Yu; H P Sun; J X Liu; X S Li; W Wu; F Q Zhang; Y Chen; L Zhou; J M Li; X Y Zeng; R R Yang; M M Yuan; M Y Ren; F Y Gu; Q Cao; B W Gu; X Y Su; G Q Chen; S M Xiong; T D Zhang; S Waxman; Z Y Wang; Z Chen; J Hu; Z X Shen; S J Chen
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

5.  Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

Authors:  Xiao-Wei Zhang; Xiao-Jing Yan; Zi-Ren Zhou; Fei-Fei Yang; Zi-Yu Wu; Hong-Bin Sun; Wen-Xue Liang; Ai-Xin Song; Valérie Lallemand-Breitenbach; Marion Jeanne; Qun-Ye Zhang; Huai-Yu Yang; Qiu-Hua Huang; Guang-Biao Zhou; Jian-Hua Tong; Yan Zhang; Ji-Hui Wu; Hong-Yu Hu; Hugues de Thé; Sai-Juan Chen; Zhu Chen
Journal:  Science       Date:  2010-04-09       Impact factor: 47.728

Review 6.  From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia.

Authors:  Sai-Juan Chen; Guang-Biao Zhou; Xiao-Wei Zhang; Jian-Hua Mao; Hugues de Thé; Zhu Chen
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

7.  GLI1 is a direct transcriptional target of EWS-FLI1 oncoprotein.

Authors:  Elspeth Beauchamp; Gulay Bulut; Ogan Abaan; Kevin Chen; Akil Merchant; William Matsui; Yoshimi Endo; Jeffrey S Rubin; Jeffrey Toretsky; Aykut Uren
Journal:  J Biol Chem       Date:  2009-02-03       Impact factor: 5.157

8.  Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.

Authors:  Elizabeth Fox; Bassem I Razzouk; Brigitte C Widemann; Shaun Xiao; Michelle O'Brien; Wendy Goodspeed; Gregory H Reaman; Susan M Blaney; Anthony J Murgo; Frank M Balis; Peter C Adamson
Journal:  Blood       Date:  2007-10-24       Impact factor: 22.113

9.  Arsenic trioxide is highly cytotoxic to small cell lung carcinoma cells.

Authors:  Helen M Pettersson; Alexander Pietras; Matilda Munksgaard Persson; Jenny Karlsson; Leif Johansson; Maria C Shoshan; Sven Påhlman
Journal:  Mol Cancer Ther       Date:  2009-01       Impact factor: 6.261

10.  A pharmacokinetic and safety study of intravenous arsenic trioxide in adult cancer patients with renal impairment.

Authors:  Christopher J Sweeney; Chris Takimoto; Leslie Wood; Jennifer M Porter; William G Tracewell; Mona Darwish; Denise M D'Andrea; Scot C Remick
Journal:  Cancer Chemother Pharmacol       Date:  2009-11-13       Impact factor: 3.333
View more
  5 in total

Review 1.  Challenges and opportunities in childhood cancer drug development.

Authors:  Robin E Norris; Peter C Adamson
Journal:  Nat Rev Cancer       Date:  2012-10-11       Impact factor: 60.716

Review 2.  Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.

Authors:  Cormac Owens; Lesleigh S Abbott; Abha A Gupta
Journal:  Paediatr Drugs       Date:  2013-12       Impact factor: 3.022

3.  One oncogene, several vulnerabilities: EWS/FLI targeted therapies for Ewing sarcoma.

Authors:  Guillermo Flores; Patrick J Grohar
Journal:  J Bone Oncol       Date:  2021-12-01       Impact factor: 4.072

4.  Blocking signaling at the level of GLI regulates downstream gene expression and inhibits proliferation of canine osteosarcoma cells.

Authors:  Mehdi Hayat Shahi; Roseline Holt; Robert B Rebhun
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

Review 5.  Targeting the undruggable: exploiting neomorphic features of fusion oncoproteins in childhood sarcomas for innovative therapies.

Authors:  Maximilian M L Knott; Tilman L B Hölting; Shunya Ohmura; Thomas Kirchner; Florencia Cidre-Aranaz; Thomas G P Grünewald
Journal:  Cancer Metastasis Rev       Date:  2019-12       Impact factor: 9.264
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.